WallStreetZenWallStreetZen

NASDAQ: SBFM
Sunshine Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SBFM stock forecasts and price targets.

Forecast return on equity

Is SBFM forecast to generate an efficient return?

Company
-0.29%
Industry
105.8%
Market
137.8%
SBFM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SBFM forecast to generate an efficient return on assets?

Company
-0.24%
Industry
13.79%
SBFM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SBFM earnings per share forecast

What is SBFM's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.99
Avg 2 year Forecast
-$0.41

SBFM revenue forecast

What is SBFM's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$36.5M+3.31%
Avg 2 year Forecast
$45.9M+29.86%
SBFM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SBFM revenue growth forecast

How is SBFM forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
3.31%
Industry
7.1%
Market
19.93%
SBFM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SBFM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SBFM vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
SBFM$3.33N/AN/A
IMCC$0.91N/AN/A
AKAN$1.10N/AN/A
UPC$1.54N/AN/A
SXTC$3.55N/AN/A
View Top Pharmaceutical Stocks

Sunshine Biopharma Stock Forecast FAQ

What is SBFM's earnings growth forecast for 2026-2027?

(NASDAQ: SBFM) Sunshine Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 24.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,302.87%.

Sunshine Biopharma's earnings in 2026 is -$5,832,664.On average, 3 Wall Street analysts forecast SBFM's earnings for 2026 to be -$385,601, with the lowest SBFM earnings forecast at -$370,480, and the highest SBFM earnings forecast at -$396,943.

In 2027, SBFM is forecast to generate -$79,098 in earnings, with the lowest earnings forecast at -$75,996 and the highest earnings forecast at -$81,424.

If you're new to stock investing, here's how to buy Sunshine Biopharma stock.

What is SBFM's revenue growth forecast for 2026-2027?

(NASDAQ: SBFM) Sunshine Biopharma's forecast annual revenue growth rate of 3.31% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.93%.

Sunshine Biopharma's revenue in 2026 is $35,346,772.On average, 3 Wall Street analysts forecast SBFM's revenue for 2026 to be $7,079,247, with the lowest SBFM revenue forecast at $6,801,630, and the highest SBFM revenue forecast at $7,287,461.

In 2027, SBFM is forecast to generate $8,898,495 in revenue, with the lowest revenue forecast at $8,549,535 and the highest revenue forecast at $9,160,216.

What is SBFM's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: SBFM) forecast ROA is -0.24%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 13.79%.

What is SBFM's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SBFM) Sunshine Biopharma's current Earnings Per Share (EPS) is -$203.00. On average, analysts forecast that SBFM's EPS will be -$1.99 for 2026, with the lowest EPS forecast at -$1.91, and the highest EPS forecast at -$2.05. In 2027, SBFM's EPS is forecast to hit -$0.41 (min: -$0.39, max: -$0.42).

What is SBFM's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: SBFM) forecast ROE is -0.29%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.